Myasthenia gravis

A review

Annapurni Jayam Trouth, Alok Dabi, Noha Solieman, Mohankumar Kurukumbi, Janaki Kalyanam

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Acquired myasthenia gravis is a relatively uncommon disorder, with prevalence rates that have increased to about 20 per 100,000 in the US population. This autoimmune disease is characterized by muscle weakness that fluctuates, worsening with exertion, and improving with rest. In about two-thirds of the patients, the involvement of extrinsic ocular muscle presents as the initial symptom, usually progressing to involve other bulbar muscles and limb musculature, resulting in generalized myasthenia gravis. Although the cause of the disorder is unknown, the role of circulating antibodies directed against the nicotinic acetylcholine receptor in its pathogenesis is well established. As this disorder is highly treatable, prompt recognition is crucial. During the past decade, significant progress has been made in our understanding of the disease, leading to new treatment modalities and a significant reduction in morbidity and mortality.

Original languageEnglish (US)
Article number874680
JournalAutoimmune Diseases
Volume1
Issue number1
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Myasthenia Gravis
Patient Participation
Muscles
Muscle Weakness
Nicotinic Receptors
Autoimmune Diseases
Extremities
Morbidity
Mortality
Antibodies
Population

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology and Microbiology (miscellaneous)
  • Immunology

Cite this

Jayam Trouth, A., Dabi, A., Solieman, N., Kurukumbi, M., & Kalyanam, J. (2012). Myasthenia gravis: A review. Autoimmune Diseases, 1(1), [874680]. https://doi.org/10.1155/2012/874680

Myasthenia gravis : A review. / Jayam Trouth, Annapurni; Dabi, Alok; Solieman, Noha; Kurukumbi, Mohankumar; Kalyanam, Janaki.

In: Autoimmune Diseases, Vol. 1, No. 1, 874680, 2012.

Research output: Contribution to journalArticle

Jayam Trouth, A, Dabi, A, Solieman, N, Kurukumbi, M & Kalyanam, J 2012, 'Myasthenia gravis: A review', Autoimmune Diseases, vol. 1, no. 1, 874680. https://doi.org/10.1155/2012/874680
Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: A review. Autoimmune Diseases. 2012;1(1). 874680. https://doi.org/10.1155/2012/874680
Jayam Trouth, Annapurni ; Dabi, Alok ; Solieman, Noha ; Kurukumbi, Mohankumar ; Kalyanam, Janaki. / Myasthenia gravis : A review. In: Autoimmune Diseases. 2012 ; Vol. 1, No. 1.
@article{c031211b47864251b80d50365bf7571e,
title = "Myasthenia gravis: A review",
abstract = "Acquired myasthenia gravis is a relatively uncommon disorder, with prevalence rates that have increased to about 20 per 100,000 in the US population. This autoimmune disease is characterized by muscle weakness that fluctuates, worsening with exertion, and improving with rest. In about two-thirds of the patients, the involvement of extrinsic ocular muscle presents as the initial symptom, usually progressing to involve other bulbar muscles and limb musculature, resulting in generalized myasthenia gravis. Although the cause of the disorder is unknown, the role of circulating antibodies directed against the nicotinic acetylcholine receptor in its pathogenesis is well established. As this disorder is highly treatable, prompt recognition is crucial. During the past decade, significant progress has been made in our understanding of the disease, leading to new treatment modalities and a significant reduction in morbidity and mortality.",
author = "{Jayam Trouth}, Annapurni and Alok Dabi and Noha Solieman and Mohankumar Kurukumbi and Janaki Kalyanam",
year = "2012",
doi = "10.1155/2012/874680",
language = "English (US)",
volume = "1",
journal = "Autoimmune Diseases",
issn = "2090-0422",
publisher = "Hindawi Publishing Corporation",
number = "1",

}

TY - JOUR

T1 - Myasthenia gravis

T2 - A review

AU - Jayam Trouth, Annapurni

AU - Dabi, Alok

AU - Solieman, Noha

AU - Kurukumbi, Mohankumar

AU - Kalyanam, Janaki

PY - 2012

Y1 - 2012

N2 - Acquired myasthenia gravis is a relatively uncommon disorder, with prevalence rates that have increased to about 20 per 100,000 in the US population. This autoimmune disease is characterized by muscle weakness that fluctuates, worsening with exertion, and improving with rest. In about two-thirds of the patients, the involvement of extrinsic ocular muscle presents as the initial symptom, usually progressing to involve other bulbar muscles and limb musculature, resulting in generalized myasthenia gravis. Although the cause of the disorder is unknown, the role of circulating antibodies directed against the nicotinic acetylcholine receptor in its pathogenesis is well established. As this disorder is highly treatable, prompt recognition is crucial. During the past decade, significant progress has been made in our understanding of the disease, leading to new treatment modalities and a significant reduction in morbidity and mortality.

AB - Acquired myasthenia gravis is a relatively uncommon disorder, with prevalence rates that have increased to about 20 per 100,000 in the US population. This autoimmune disease is characterized by muscle weakness that fluctuates, worsening with exertion, and improving with rest. In about two-thirds of the patients, the involvement of extrinsic ocular muscle presents as the initial symptom, usually progressing to involve other bulbar muscles and limb musculature, resulting in generalized myasthenia gravis. Although the cause of the disorder is unknown, the role of circulating antibodies directed against the nicotinic acetylcholine receptor in its pathogenesis is well established. As this disorder is highly treatable, prompt recognition is crucial. During the past decade, significant progress has been made in our understanding of the disease, leading to new treatment modalities and a significant reduction in morbidity and mortality.

UR - http://www.scopus.com/inward/record.url?scp=84872942199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872942199&partnerID=8YFLogxK

U2 - 10.1155/2012/874680

DO - 10.1155/2012/874680

M3 - Article

VL - 1

JO - Autoimmune Diseases

JF - Autoimmune Diseases

SN - 2090-0422

IS - 1

M1 - 874680

ER -